Rani Therapeutics Holdings, Inc. (RANI)
NASDAQ: RANI · Real-Time Price · USD
1.350
-0.010 (-0.74%)
At close: Jan 21, 2026, 4:00 PM EST
1.330
-0.020 (-1.48%)
Pre-market: Jan 22, 2026, 7:48 AM EST
RANI Revenue
Rani Therapeutics Holdings had revenue of $1.20M in the twelve months ending September 30, 2025. In the year 2024, Rani Therapeutics Holdings had annual revenue of $1.03M.
Revenue (ttm)
$1.20M
Revenue Growth
n/a
P/S Ratio
41.98
Revenue / Employee
$11,321
Employees
106
Market Cap
164.05M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.03M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 2.72M | 2.26M | 488.10% |
| Dec 31, 2020 | 462.00K | -517.00K | -52.81% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vaxart | 148.20M |
| Century Therapeutics | 113.34M |
| Protalix BioTherapeutics | 61.84M |
| Innate Pharma | 14.84M |
| Opus Genetics | 14.63M |
| Prelude Therapeutics | 10.50M |
| Surrozen | 3.60M |
| Molecular Partners AG | 856.30K |
RANI News
- 14 days ago - Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen - GlobeNewsWire
- 2 months ago - Rani Therapeutics to Participate in the Evercore Healthcare Conference - GlobeNewsWire
- 2 months ago - Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update - GlobeNewsWire
- 3 months ago - Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025 - GlobeNewsWire
- 3 months ago - Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors - GlobeNewsWire
- 3 months ago - Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules - GlobeNewsWire
- 3 months ago - Rani Therapeutics: Initiating At Buy On Promising RaniPill Advancement With Chugai - Seeking Alpha
- 3 months ago - CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why - Invezz